--- title: "Viking Therapeutics (NASDAQ:VKTX) Trading 1.2% Higher - Here's What Happened" description: "Viking Therapeutics (NASDAQ:VKTX) shares rose 1.2% to $0.37, with a trading volume significantly lower than average. Analysts have mixed ratings, with Oppenheimer and HC Wainwright maintaining 'outper" type: "news" locale: "en" url: "https://longbridge.com/en/news/217266687.md" published_at: "2024-10-18T18:11:55.000Z" --- # Viking Therapeutics (NASDAQ:VKTX) Trading 1.2% Higher - Here's What Happened > Viking Therapeutics (NASDAQ:VKTX) shares rose 1.2% to $0.37, with a trading volume significantly lower than average. Analysts have mixed ratings, with Oppenheimer and HC Wainwright maintaining 'outperform' and 'buy' ratings, respectively. The stock has a market cap of $0.19 billion and a PE ratio of -70.29. Recent insider sales include CEO Brian Lian selling 216,130 shares. Hedge funds have also increased their stakes in the company. Analysts expect a consensus target price of $0.60 for VKTX. Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) shares rose 1.2% on Friday . The company traded as high as $65.86 and last traded at $65.37. Approximately 251,694 shares changed hands during trading, a decline of 94% from the average daily volume of 4,312,246 shares. The stock had previously closed at $64.61. Get **Viking Therapeutics** alerts: ## Wall Street Analyst Weigh In - Is Viking Therapeutics Ready For Another Surge? VKTX has been the topic of a number of research reports. Oppenheimer restated an "outperform" rating and issued a $138.00 price target on shares of Viking Therapeutics in a research note on Wednesday, September 25th. HC Wainwright restated a "buy" rating and set a $90.00 price target on shares of Viking Therapeutics in a research note on Wednesday, October 9th. Morgan Stanley reiterated an "overweight" rating and issued a $105.00 price objective on shares of Viking Therapeutics in a research note on Thursday, September 12th. StockNews.com upgraded Viking Therapeutics to a "sell" rating in a research report on Tuesday. Finally, Raymond James boosted their target price on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Viking Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $108.60. **Get Our Latest Research Report on VKTX** ## Viking Therapeutics Price Performance - Viking Therapeutics Is Having a Year to Remember: Time to Buy? The stock's fifty day simple moving average is $62.47 and its 200-day simple moving average is $62.16. The firm has a market cap of $7.19 billion, a PE ratio of -70.29 and a beta of 1.00. Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.06. During the same period last year, the company earned ($0.19) earnings per share. Analysts expect that Viking Therapeutics, Inc. will post -1 earnings per share for the current year. ## Insiders Place Their Bets - Viking Therapeutics: Pharma Stock Soars on Positive Earnings In other Viking Therapeutics news, CEO Brian Lian sold 216,130 shares of the firm's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $70.83, for a total value of $15,308,487.90. Following the completion of the sale, the chief executive officer now directly owns 2,304,927 shares of the company's stock, valued at $163,257,979.41. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Viking Therapeutics news, Director J Matthew Singleton sold 20,786 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.53, for a total value of $1,195,818.58. Following the transaction, the director now owns 9,500 shares of the company's stock, valued at $546,535. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the sale, the chief executive officer now owns 2,304,927 shares of the company's stock, valued at approximately $163,257,979.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 516,671 shares of company stock valued at $33,810,813 in the last ninety days. 4.70% of the stock is currently owned by corporate insiders. ## Hedge Funds Weigh In On Viking Therapeutics Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 243 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in shares of Viking Therapeutics by 84.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 253 shares in the last quarter. 9258 Wealth Management LLC boosted its stake in shares of Viking Therapeutics by 2.9% in the first quarter. 9258 Wealth Management LLC now owns 12,379 shares of the biotechnology company's stock valued at $1,015,000 after purchasing an additional 351 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Viking Therapeutics by 3.1% in the second quarter. Los Angeles Capital Management LLC now owns 12,278 shares of the biotechnology company's stock valued at $651,000 after purchasing an additional 372 shares during the period. Finally, Crossmark Global Holdings Inc. grew its holdings in shares of Viking Therapeutics by 5.5% in the second quarter. Crossmark Global Holdings Inc. now owns 7,457 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock. ## About Viking Therapeutics (Get Free Report) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. ## Featured Stories - Five stocks we like better than Viking Therapeutics - Industrial Products Stocks Investing - Survey Reveals: America’s Most Coveted Businesses in 2024 - What is the Euro STOXX 50 Index? - Top 3 Stocks to Play Oil’s Potential Comeback Rally - Biggest Stock Losers - Today’s Biggest Percentage Decliners - Analysts See Growth in CrowdStrike Stock Despite July Setback *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → Strange gold laws spreading (From Stansberry Research) (Ad)## Should you invest $1,000 in Viking Therapeutics right now? Before you consider Viking Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list. While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [VKTX.US - Viking Therap](https://longbridge.com/en/quote/VKTX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | BUZZ-Viking 治疗公司股价上涨，因其计划在后期研究中测试口服肥胖药物 | Viking Therapeutics 的股票上涨了 9.4%，至 31.24 美元，此前该公司宣布计划在第三季度将其口服肥胖药 VK2735 推进至后期试验。VKTX 强调提供口服和注射两种剂型的重要性，因为目前没有其他双重或三重激动剂同 | [Link](https://longbridge.com/en/news/275665780.md) | | Viking Therapeutics 公布 2025 财年的研究与开发费用为 3.45 亿美元 | Viking Therapeutics Inc. 报告其 2025 财年的研发费用为 3.45 亿美元，未产生任何收入，因为尚未商业化任何药物候选者。这些费用因 VK2735 和 VK2809 的临床试验而显著增加。公司在其产品线方面取得了 | [Link](https://longbridge.com/en/news/275668350.md) | | Viking CEO 表示，减肥交易的需求比表面上看到的更为广泛 | Viking Therapeutics 首席执行官 Brian Lian 表示，对减肥药物交易的兴趣比看起来更广泛，因为制药公司旨在进入预计达到 1500 亿美元的市场。关键的增长因素包括扩展的临床应用和下一代疗法。Lian 指出，公司正在 | [Link](https://longbridge.com/en/news/272335070.md) | | Viking 治疗在最新的公司展示中展示了其在肥胖和代谢疾病领域的研发进展 | Viking Therapeutics Inc. 发布了一份企业演示文稿，重点介绍其在代谢和内分泌疾病领域的管线进展。值得注意的更新包括正在进行的 VK2735 的第三阶段 VANQUISH 计划，这是一种用于肥胖的双重 GLP-1/GIP | [Link](https://longbridge.com/en/news/272603256.md) | | Viking 治疗公司报告称，第二阶段试验结果显示，VK2735 在肥胖患者中实现了最高 14.7% 的体重减轻 | Viking Therapeutics Inc. 报告称，其 VK2735 的第二阶段 VENTURE 试验显示，在 13 周后，肥胖患者的体重减轻高达 14.7%，且结果没有出现平台期。该治疗耐受性良好，主要的不良事件为轻度或中度。VK2 | [Link](https://longbridge.com/en/news/272265172.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.